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Abstract
Objective—To estimate the frequency of self-reported fecal incontinence (FI), identify what
proportion of these patients have a diagnosis of FI in their medical record, and compare healthcare
costs and utilization in patients with different severities of FI to those without FI.
Study Design—Patients in a healthcare maintenance organization were eligible and 1707
completed a survey. Patients with self-reported FI were assessed for a diagnosis of FI in their
medical record for the last five years. Healthcare costs and utilization were obtained from claims
data.
Results—Fecal incontinence was reported by 36.2% of primary care patients, but only 2.7% of
patients with FI had a medical diagnosis. FI adversely affected quality of life and severe FI was
associated with 55% higher healthcare costs (including 77% higher gastrointestinal-related
healthcare costs) compared to continent patients.
Conclusions—Increased screening of FI is needed.
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INTRODUCTION
Fecal incontinence (FI), which is defined as the accidental loss of solid or liquid stool,
affects a large proportion of the non-institutionalized population of the United States.
Estimates range from 2.2%1 to as high as 24%2, with most estimates in the range of 7–
12%3;4. It has a significant impact on quality of life which may include embarrassment,
social stigmatization, depression and anxiety5–7. FI may also contribute to the decision to
place older patients into assisted living facilities8. However, despite its high prevalence, its
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deleterious impact on quality of life, and the availability of effective medical and surgical
treatments9;10, surveys suggest that only 10%7 to 30%11 of people with FI have discussed
this with their physician.
The direct costs associated with providing care for patients with FI are largely unknown.
This is due in part to the variety of treatments, ranging from medical and behavioral
approaches to surgical repair9;10 with very different costs, and also the failure of most cost
analyses to differentiate between FI and urinary incontinence5;12.
The aims of this study were to: (1) estimate the prevalence of FI in primary care and its
impact on quality of life and healthcare costs, (2) determine what proportion of patients with
self-reported FI have a medical diagnosis of FI, (3) identify patient characteristics that
increase the likelihood that FI is reported to a physician and diagnosed, and (4) estimate
healthcare costs associated with FI. It is our hypothesis that patients who self-report FI are
often undiagnosed and that those who self-report FI utilize more total and more GI related
healthcare dollars, make more healthcare visits, and have lower health-related quality of life.
MATERIALS AND METHODS
This study represents a secondary analysis of a larger study (Nguyen TV, Palsson OS, Von
Korff M et al. Satisfaction with laxatives in chronic constipation and irritable bowel with
constipation. under review). Briefly, a large prospective study was performed to assess the
impact of chronic constipation on quality of life and healthcare costs at a health management
organization (HMO), Group Health Cooperative of Puget Sound (GHC), which serves more
than half a million residents in the state of Washington. GHC’s patient population is similar
to the general population of Seattle, except that it under-represents the high and low
extremes of socioeconomic status. When compared to the United States census, the study
population under-represents Hispanics and African Americans and over-represents Asians.
All patients were required to be at least 18 years old, to have made at least one clinic visit
(index visit) to a primary care provider at GHC between September 1, 2004 and December
31, 2005, and to have been enrolled at GHC for all of the previous 5 years. Gynecology
clinics were included with other primary care clinics. Exclusions were a history of
gastrointestinal cancer or resection except for appendectomy or cholecystectomy. Two
groups were recruited: 676 patients with a clinical diagnosis of constipation (564.0X) at
their index visit, and a control group of 1031 patients who were matched by stratified
sampling to the constipated patients with respect to age and sex but who did not receive a
clinical diagnosis of constipation either at their index visit or at any time in the previous 5
years. Controls were matched to constipated patients using a stratified sampling frame to
recruit a specified number in each age range of both males and females. This control group
was unselected except for age and sex and the exclusion of a clinical diagnosis of
constipation.
The study received institutional review board approval by both the University of North
Carolina at Chapel Hill and GHC. Patients received a full description of the study with all
elements of informed consent. Informed consent was inferred from completion and return of
the questionnaires.
The survey included questions about the patient’s symptoms and history of constipation; the
Rome III Diagnostic Questionnaire13 modules for functional constipation, IBS, and bloating;
demographic information; and the SF-12 Health Survey. The SF-12 is a generic health-
related quality of life scale whose 12 questions address self-perceptions of both physical and
mental health14. It is scored by summing items on physical and mental scales and
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transforming these into T-scores such that a score of 50 corresponds to the mean for the
healthy adult population and one standard deviation below the mean for healthy controls is
equivalent to a T-score of 40. A difference of 5 units is considered the minimally clinically
important difference.
Patients were classified as fecally continent or incontinent based on their response to the
following question in the initial survey: “In the last 3 months, how often have you
accidentally leaked liquid or solid stool?” Response options were never, less than one day a
month, one day a month, two to three days a month, one day a week, more than one day a
week, or every day. Patients who answered “never” were classified as continent, those who
answered “one day a month” or less often were categorized as infrequent FI, and those who
answered “two to three days a month” or more often were categorized as frequent FI, similar
to Bharucha6.
Healthcare costs and healthcare utilization were calculated (for consenting patients) from
claims data collected by GHC for the previous 5 years using previously described
methods15. Outliers were accounted for by averaging cost and utilization data for each
patient over a 5-year period; 5-year means were the unit of analysis. Actual costs (not
charges) were expressed in 2005 US$. The average number of inpatient days for 5 years was
obtained from these claim data and used as an index of medical comorbidity. This
unvalidated index is conceptually similar to the Charlson comorbidity index, with which it
correlates16.
Statistical analyses were performed using SPSS version 16.0 software (SPSS Inc., Chicago,
IL). Fisher’s Exact Test was used for dichotomous data and Student’s t-test was used for
continuous variables when the comparison groups were of similar size; however, for
comparison of the 15 patients with medical diagnosis of FI to the 535 FI patients without a
medical diagnosis, Mann-Whitney U tests were employed. General linear modeling was
used to test for mediation. A p-value of < 0.05 was considered significant.
RESULTS
The control cohort included 1003 analyzable patients after excluding 28 who had missing
data for the FI question. The constipation cohort included 655 patients after excluding 21
with missing data for the FI question. Average age was 66.29 years for controls and 66.02
years for constipated patients; 68% of controls and 69% of constipated patients were female.
Table 1 shows that FI at least once in the past month was reported by 34.1% (342/1003
patients) in the control cohort and by 39.4% (258/655 patients) in the constipated cohort
(p=0.074). The overall prevalence of FI was 36.2%. Frequent (≥2 times/month) FI was
reported by 10.7% of controls and 13.3% of constipated patients. Because there was no
significant difference between those with a clinical diagnosis of constipation and those
without, the two cohorts were pooled in subsequent analyses.
Table 1 also shows that patients meeting the symptom criteria for IBS were significantly
more likely to report FI compared to patients without IBS. Having loose stools “often” or
“always” was highly predictive of frequent FI, and having hard stools “often” or “always”
was weakly predictive of FI. The relationship between IBS diagnosis and FI was not
explained by the effects of loose stools because, when analysis was restricted to patients
who reported loose stools and hard stools “never” or “sometimes”, those with IBS were still
more likely to report frequent FI (13.9% compared to 5.8% for non-IBS patients; χ2=23.004;
p<0.001).
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Demographic variables that have been reported to influence the development of FI are
shown in Table 2. FI was significantly associated with age, marital status, and race but not
sex, education, or income.
The physical component of quality of life (i.e., the ability to engage in daily physical
activities such as shopping and climbing stairs) was significantly lower in patients with FI,
but the mental component was not (Table 3). This association was confirmed by multivariate
analysis adjusting for IBS diagnosis, loose stools, hard stools, age, marital status, race, and
inpatient bed days.
Average annual healthcare costs for all causes was significantly associated with FI, with
patients who had frequent FI having an average of $2897 per year higher health care costs
than patients without FI. This association was confirmed by multivariate analysis adjusting
for IBS diagnosis, loose stools, hard stools, inpatient bed days, age, race, and marital status.
Gastrointestinal (GI) related health care costs were significantly related to FI in univariate
analyses, but this relationship did not survive multivariate testing. Likewise, the frequency
of health care visits was significantly higher in patients with frequent FI compared to
patients without FI (average difference of 4.21 visits per year). This association was also
confirmed by multivariate testing. Univariate testing showed the number of GI-related
outpatient visits to be significantly increased in patients with frequent FI compared to those
without FI, but this was no longer significant after multivariate adjustment. Figure 1 shows
the proportion of primary care patients who had a medical diagnosis of FI. Only 15 patients
with self-reported FI had a clinical diagnosis of FI in the medical record for the last 5 years
(2.7% of those with self-reported FI; 1% of all evaluable patients). This analysis was limited
to patients who gave permission for review of their medical records (550 with self-reported
FI and 920 without self-reported FI). Ten of the 15 patients with a medical diagnosis of FI
came from the control cohort and 5 from the constipated cohort. (Fifty patients who reported
FI on questionnaires did not give permission for review of their medical records.)
The next set of analyses investigated factors that may influence which patients with FI
receive a medical diagnosis of FI. Nine of 15 patients with a medical diagnosis of FI had 2
or more accidents per month, and this association was significant at p=0.023. Ten of 15
patients with a medical diagnosis of FI had IBS, but the association of IBS to medical
diagnosis of FI was not statistically significant due to the large number of IBS patients with
FI who did not receive a medical diagnosis for it. Neither diarrhea nor constipation was
predictive of receiving a medical diagnosis for FI.
We also examined whether patients with the greatest impact of FI on their quality of life
were the most likely to receive a medical diagnosis, but found no evidence for this (Table 4).
We did find that patients who received a medical diagnosis of FI had significantly higher
GI-related health care costs, increased numbers of outpatient visits overall, and increased
numbers of GI-related outpatient visits.
COMMENT
These data show that FI is highly prevalent among older medical patients in the primary care
clinics of an HMO – a third are affected-- and this problem is usually undiagnosed-- only 15
(2.7%) with self-reported FI had a clinical diagnosis of FI in their medical record for the last
5 years. This is important because it shows that healthcare providers are not actively
screening for FI and it suggests that patients may be pessimistic that physicians can help
with this problem. Others have also reported that the majority of patients with FI do not
report this to their physician17. This low rate of screening and care-seeking is unfortunate
because there are a variety of treatments that can reduce the severity of FI and in some cases
eliminate it altogether.
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Others have reported that patients with more frequent symptoms of FI are more likely to
consult their physicians7 and our data confirm this. However, it is important to recognize
that not all patients with frequent FI report it to their physician: in this study, 95% of
patients with frequent FI had no medical diagnosis of FI.
FI had a significant impact on the physical but not the mental aspects of quality of life even
in patients who had not discussed their FI with their doctor. The impact on the physical
components of quality of life was greater than a half standard deviation (decrease from a T-
score of 44.9 to 36.6) which meets the accepted definition of a clinically meaningful effect.
The failure to see an impact of FI on the mental component of quality of life contrasts with
other studies which have reported a significant impact on anxiety, depression, and
willingness to socialize6;18. The most likely explanation for this disparity is that the SF12 is
a generic quality of life instrument that is not sensitive to the specific impact of FI; those
reporting a significant psychosocial impact of FI have used disease-specific instruments6.
An important observation in our study was that infrequent FI (once a month or less often)
had an effect on the physical component of quality of life comparable to that of frequent FI,
showing the importance of diagnosing and treating even the patient with “mild” or
infrequent FI.
Previously, the healthcare costs for FI have remained largely unknown because the treatment
and care of patients with FI is layered and complicated, and divergent approaches have been
used to estimate FI related costs. Several authors have looked at the costs of surgical repair
alone19;20; some have evaluated the costs associated with obstetrical injuries21, while others
have evaluated the costs of outpatient care22. Surgical costs range from € 3,724 to $17,166.
Outpatient costs have been reported at € 2,169 per patient year with more than half of the
total costs of FI made up of indirect costs22; however, this study was performed in the
Netherlands and may not be applicable to the population of the United States.
We compared total direct healthcare costs and GI-related healthcare costs between patients
who reported FI and those that did not. This approach to estimating the economic burden of
a disease has been used to estimate the economic burden of other diseases, such as
Alzheimer’s disease23 and rosacea24. Patients with frequent FI had 55% higher total
healthcare costs and 77% higher GI related healthcare costs, and they also had significantly
more total outpatient visits and GI outpatient visits. The difference in total health care cost
and utilization remained significant after adjusting for age, IBS diagnosis, medical
comorbidity, and other contributors to increased health care.
However, we cannot assume that these differences in healthcare costs are directly
attributable to surgical or medical management of FI. The discrepancy between the
incremental cost for all healthcare in patients with frequent FI ($2897) versus the smaller
incremental cost for GI related healthcare ($219) suggests that most of the excess healthcare
cost seen in patients with FI is for comorbid illnesses. This conclusion is reinforced in our
study by two other observations: First, we found that only 2.7% of patients with self-
reported FI had received a medical diagnosis for their FI, but the remaining 97.3% of
patients whose FI had not been diagnosed also had significantly higher total healthcare costs
and GI-related healthcare costs. The second observation is that the presence and the severity
of FI are both significantly associated with the total number of inpatient bed days – a
surrogate marker for the overall ill health. Thus, although we were able to show by
multivariate regression that FI is independently associated with increased health care costs
after adjusting for number of inpatient bed days and other confounders, our estimates of the
healthcare costs associated with FI should be interpreted with caution.
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There were other limitations to this study: It involved a large HMO based population, and
costs may differ for patients seen by other types of providers. However, in 1997, one quarter
of the U.S. population were enrolled in HMOs according to the National Center for Health
Statistics (www.cdc.gov/nchs/pressroom/98news/huspr98.htm). We also studied an older
population of patients, and because the prevalence of FI increases with age1, these data
likely over-estimate the prevalence of FI in younger adults. A strength of our study is that it
involved a large population and included both sexes, although in comparison to the U.S.
overall, Asians were over-represented and African-Americans were under-represented.
Another limitation is that we were not able to include out-of-pocket healthcare costs such as
the purchase of protective devices and over the counter medications, which are believed to
be large. Moreover, it is believed that FI increases the likelihood of a patient being referred
to a nursing home, and this is a significant additional healthcare costs which was not
captured in this study5.
Future directions may include (1) a more detailed analysis of medical charges to determine
what types of healthcare account for the excess costs seen in patients with FI, (2)
questionnaires targeted at capturing over-the-counter costs for pads, containment devices,
and medications; (3) methods for capturing indirect costs related to work absenteeism,
decreased work productivity, or termination of employment due to FI; and (4) studies of the
cost of nursing home referral that may be attributable to having FI.
In conclusion, FI symptoms are prevalent in an HMO setting but are rarely diagnosed. This
finding reemphasizes the importance of screening patients for FI as this is a treatable
condition that is associated with a deleterious impact on quality of life and increased
healthcare costs when left untreated. Overall, the total healthcare costs are 55% higher and
GI-related costs are 77% higher in patients with frequent FI symptoms, but it is unknown
how much of the excess healthcare costs are directly related to FI vs. being related to other
co-morbid medical conditions.
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Primary care patients who reported fecal incontinence (FI) in the past month. Only a small
fraction (2.7%) of FI patients had a medical (MD) diagnosis. Excluded from analysis were
50 with FI and 138 without FI who refused permission to review their medical records.
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Table 1
Relationship of Bowel Symptoms to Severity of Fecal Incontinence
No FI FI<2/month FI>2/month Statistical Significance
CLINICAL DIAGNOSIS OF CONSTIPATION:
 No 65.9% (n=661) 23.4% (n=235) 10.7% (n=107) χ2=5.213
P=0.074
 Yes 60.6% (n=397) 26.1% (n=171) 13.3% (n=87)
ROME CRITERIA FOR IBS:
 No 69.7% (n=739) 22.4% (n=237) 7.9% (n=84) χ2 =57.793
P<0.001
 Yes 53.1% (n=312) 28.6% (n=168) 18.4% (n=108)
LOOSE STOOLS:
 Never or sometimes 67.2% (n=1006) 23.6% (n=353) 9.3% (n=139) χ2 =113.906
P<0.001
 Often or always 31.0% (n=48) 34.2% (n=53) 34.8% (n=54)
HARD STOOLS:
 Never or sometimes 65.5% (n=791) 23.8% (n=288) 10.7% (n=129) χ2=6.151
P=0.046
 Often or always 59.3% (n=261) 26.6% (n=117) 14.1% (n=62)
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Table 2
Demographics in patient subgroups defined by severity of Fecal Incontinence
No FI FI<2/month FI≥2/month Statistical Significance
AGE: (mean years) 63.2 69.6 73.6 F=14.513, P<0.001
SEX:
 Females 53.6% (n=719) 23.2% (n=260) 12.7% (n=142) χ2=4.464
P=0.107
 Males 63.5% (n=333) 26.7% (n=140) 9.7% (n=51)
MARITAL STATUS:
Single, separated, divorced or widowed 57.8% (n=312) 26.3% (n=142) 15.9% (n=86) χ2 =17.965
P<0.001
Living with partner or married 66.9% (n=739) 23.4% (n=259) 9.7% (n=107)
EDUCATION:
High school or less 62.7% (n=235) 24.3% (n=91) 13.1% (n=44) χ2=0.998
P=0.607
College or professional 64.4% (n=816) 24.4% (n=309) 11.2% (n=142)
RACE:
Caucasian 62.7% (n=912) 25.3% (n=368) 12.0% (n=174) χ2=6.697
P=0.035
Other races 71.9% (n=146) 18.2% (n=37) 9.9% (n=20)
PERSONAL INCOME:
$0–49,999 62.4% (n=653) 25.0% (n=262) 12.5% (n=131) χ2=6.354
P=0.174
$50,000–99,000 68.1% (n=246) 23.5% (n=85) 8.3% (n=30)
$100,000 or greater 68.5% (n=37) 20.4% (n=11) 11.1% (n=6)
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Table 4
Differences between Fecally Incontinent Patients with versus those without a Medical Diagnosis: Quality of
Life, Healthcare Costs, and Healthcare Utilization
FI but no Diagnosis FI with Diagnosis p-value*
SF-12 Physical Composite 39.32 35.17 0.218
SF-12 Mental Composite 51.10 51.14 0.670
All Cause Health Care Costs $7312 $8900 0.114
GI Related Costs $412 $635 0.043
All Cause Outpatient Visits 10.60 17.75 0.001
GI Outpatient Visits 0.58 1.09 0.003
*
Significance tested by Mann-Whitney non-parametric test due to small sample size for one group.
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